NCT00763607已完成不适用
Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer
Armando Santoro, MD1 个研究点 分布在 1 个国家目标入组 454 人开始时间: 2007年11月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 454
- 试验地点
- 1
- 主要终点
- Association of different biomarkers with survival
研究概览
简要总结
Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients
The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Radically resected non small cell lung cancer patients with tumor tissue available
排除标准
- •Tumor tissue not available
- •Clinical data not available
结局指标
主要结局
Association of different biomarkers with survival
时间窗: At the end of enrollment
次要结局
- Association of a specific biomarker with patient's characteristics(At the end of enrollment)
研究者
Armando Santoro, MD
MD
Istituto Clinico Humanitas
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural MesotheliomaMalignant Pleural MesotheliomaNCT00484276AGC Biologics S.p.A.57
暂停
2 期
Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.Chronic Heart FailureNCT01235273Federico II University100
撤回
2 期
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and PaclitaxelLung NeoplasmsCarcinoma, Non-Small-Cell LungNCT00768131Eli Lilly and Company
已完成
2 期
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung CarcinomaSmall Cell Lung CancerNCT00483509AGC Biologics S.p.A.28
已完成
2 期
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT00484211AGC Biologics S.p.A.40